Pramlintide (Symlin)
Weight Management & Metabolic Peptidefda_approvedAlso known as: Symlin, Symlinpen, AC-137
FDA-approved synthetic analog of amylin, a peptide hormone co-secreted with insulin. Used alongside insulin for diabetes management, it slows gastric emptying, reduces glucagon, and promotes satiety — leading to weight loss.
Overview
Pramlintide is a synthetic analog of human amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin by pancreatic beta cells. In type 1 diabetes and advanced type 2 diabetes, amylin production is deficient along with insulin. Pramlintide replaces this missing hormone, providing complementary glucose control through mechanisms distinct from insulin: slowing gastric emptying, suppressing inappropriate glucagon secretion, and increasing satiety. It is notable in the peptide therapy community for its weight loss effects, as it can reduce body weight by 1-3 kg in clinical trials.
Mechanism of Action
Pramlintide mimics native amylin through: (1) Slows gastric emptying, reducing the rate of glucose appearance in blood after meals; (2) Suppresses inappropriate postprandial glucagon secretion; (3) Promotes satiety through central nervous system signaling; (4) Reduces postprandial glucose spikes; (5) May reduce food intake by 20-30% through CNS appetite suppression; (6) Works synergistically with insulin to improve overall glucose control.
Molecular Formula
C171H267N51O53S2
Molecular Weight
3949.4 g/mol
Sequence
37 amino acid peptide with Pro substitutions at positions 25, 28, 29
Dosage Protocols
Dose Range
60mcg – 120mcg
Frequency
Before major meals
Route
subcutaneous injection
Cycle Length
Ongoing
Start at 60mcg, increase to 120mcg after 3-7 days if tolerated. Inject immediately before meals. Reduce insulin dose by 50% when starting.
Source: FDA prescribing information
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
SymlinPen 60/120
Last Updated
2026-02
Brand name Symlin. No generic available. Insurance coverage varies.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| moderate | |
| severe | |
| mild | |
| moderate | |
| mild |
Pros & Cons
FDA-approved with extensive clinical data
Unique mechanism complementary to insulin
Promotes weight loss (unlike insulin which causes gain)
Reduces postmeal glucose spikes
Increases satiety naturally
Well-established dosing protocols
Must be injected separately from insulin
Nausea is very common initially
Requires careful insulin dose adjustment
Only FDA-approved for diabetes (not general weight loss)
Multiple daily injections
Can cause severe hypoglycemia if insulin not adjusted
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
FDA-approved (2005) for type 1 and type 2 diabetes as adjunct to insulin therapy. Prescription required.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Ipamorelin
A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.